Vertical Longevity Pharma
A preclinical biotech company developing a virus-like particle-based senolytic immunotherapy for atherosclerosis.
Website: https://vertical-longevity-pharma.com
Cover Block
| Name | Vertical Longevity Pharma |
| Tagline | A preclinical biotech company developing a virus-like particle-based senolytic immunotherapy for atherosclerosis. |
| Headquarters | Irvine, California |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | Other |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
Links
- Website: https://vertical-longevity-pharma.com/
- LinkedIn: https://www.linkedin.com/posts/vertical-longevity-pharmaceuticals_honored-to-have-our-ceo-david-scieszka-win-activity-7404968318253772800-76Ku
- X / Twitter: https://x.com/SilaB_HV
Data Accuracy: GREEN -- Company website and social media pages are live and confirmed.
What an Investor Needs First
Vertical Longevity Pharma is a preclinical biotech startup developing a senolytic vaccine designed to clear the senescent cells that drive atherosclerosis [Netcapital]. Founded in 2024, the company's core proposition is a virus-like particle (VLP)-based immunotherapy, a platform that aims to offer a more precise alternative to small-molecule senolytics by mimicking a viral infection to trigger an immune response against harmful aged cells [Company site]. The founding story centers on David Scieszka, who leads the company as CEO and has articulated the scientific and commercial thesis through channels like The Bioinformatics CRO Podcast [The Bioinformatics CRO Podcast].
Early validation is limited to preclinical mouse studies, which the company reports have demonstrated plaque prevention and restoration of cardiac function, with plans to advance to primate testing [Kingscrowd, 2025]. The company has secured backing from Sila B Health Ventures and closed a Netcapital offering in January 2026 [Wixdom]. Over the next 12-18 months, the critical milestones will be the execution of its planned primate studies and the progression toward IND-enabling work.
Data Accuracy: YELLOW -- Core product claims and founder identity are confirmed via company and investor materials; funding details and preclinical data are cited but lack independent corroboration.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Undisclosed |
Inside the Company
Vertical Longevity Pharma, also referenced as Vertical Longevity Pharmaceuticals, was founded in 2024 and is headquartered in Irvine, California [F6S]. The company operates as a preclinical biotechnology entity. Founder and CEO David Scieszka has publicly framed the venture around developing a low-cost immunotherapy platform, beginning with a focus on atherosclerosis [Netcapital].
Key milestones to date follow a standard preclinical biotech trajectory. The company has reported completing initial mouse studies demonstrating plaque prevention and cardiac function restoration [Kingscrowd, 2025]. Public materials indicate plans for upcoming efficacy studies in non-human primates, a typical step toward Investigational New Drug (IND) enabling work [Company site]. Fundraising activity is confirmed, with the company having secured capital from Sila B Health Ventures and noting early-stage commitments from angel investors and a technology transfer office [F6S, Netcapital]. A Netcapital offering related to the company closed in January 2026 [Wixdom].
Data Accuracy: YELLOW -- Company details are consistent across multiple secondary profiles, but key legal and incorporation documents are not publicly cited.
Under the Hood
The company’s core proposition is a biological platform. Vertical Longevity Pharma is developing a senolytic immunotherapy, described as a “senolytic vaccine,” that uses engineered virus-like particles (VLPs) to target and clear senescent cells [Netcapital]. The initial disease target is atherosclerosis, with the aim of both preventing new plaque formation and clearing existing arterial plaques [Company site]. The technology is positioned as a low-cost alternative to other senolytic approaches, leveraging VLPs that mimic viral structures to elicit an immune response but lack infectious genetic material [Netcapital].
Preclinical validation has been conducted in mouse models. According to a third-party profile, these studies demonstrated plaque prevention and restoration of cardiac function [Kingscrowd, 2025]. The next planned step is efficacy testing in non-human primates, which the company cites as an upcoming study to establish human-relevant proof of concept [Company site]. The platform’s design suggests potential expansion into other age-related conditions [Netcapital].
Data Accuracy: YELLOW -- Product claims are consistent across the company’s site and a funding portal, but preclinical data is cited from a single third-party profile.
Market Research
The commercial case for senolytics rests on the demographic reality that the global population is aging, and the economic burden of age-related diseases is rising. Vertical Longevity Pharma's initial focus on atherosclerosis places it at the intersection of cardiovascular disease and the broader longevity biotech sector.
| Market Segment | Cited Size Estimate | Source / Note |
|---|---|---|
| U.S. Cardiovascular Disease Costs (2035 projection) | > $1.8 trillion (cumulative) | American Heart Association report, cited in industry analysis [American Heart Association] |
| Global Longevity & Anti-Aging Therapeutics Market (2030 projection) | Tens of billions of USD (estimated) | Analyst projection based on sector growth [Longevity.Technology] |
Data Accuracy: YELLOW -- Market sizing relies on analogous third-party reports for cardiovascular disease costs and sector projections; specific TAM for a senolytic atherosclerosis vaccine is not publicly defined by the company or in cited sources.
Competition and Substitutes
Vertical Longevity Pharma is a new entrant in a specialized, high-capital-intensity field where the primary competition is for scientific validation, intellectual property, and institutional capital.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Vertical Longevity Pharma | Preclinical biotech developing a VLP-based "senolytic vaccine" for atherosclerosis. | Pre-Seed; raised from Sila B Health Ventures. Netcapital offering closed Jan 2026. | Immunotherapy approach aimed at clearing existing plaques; initial preclinical data in mice. | [Netcapital], [Wixdom] |
| Cleara Biotech | Developing senolytic therapies targeting the FOXO4-p53 interaction. | Private; Series B raised $43M in 2023. | Focus on peptide-based senolytics; multiple preclinical programs. | [Crunchbase, 2023] |
| Unity Biotechnology | Clinical-stage biotech developing senolytic medicines for ophthalmology and neurology. | Public (UBX); ~$100M market cap (April 2025). | Most advanced clinical pipeline in senolytics; lead candidate in Phase 2 for diabetic macular edema. | [Unity Biotech website] |
| Oisín Biotechnologies | Developing a lipid nanoparticle-delivered gene therapy platform for senolytic applications. | Private; non-dilutive and venture funding. | In vivo genetic reprogramming approach; platform applicable across tissues. | [Company website] |
Data Accuracy: YELLOW -- Competitor profiles are assembled from public sources and company websites; funding and stage data for competitors is dated. Vertical Longevity's positioning is confirmed by its own materials and a third-party profile.
Opportunity
If the preclinical data translates to a safe and effective human therapy, Vertical Longevity Pharma is pursuing a single-shot treatment for the world's leading cause of death.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Cardiovascular Franchise | The VLP therapy gains FDA approval for atherosclerosis, becoming a foundational treatment used in combination with statins and PCSK9 inhibitors. | Successful completion of IND-enabling studies and initiation of Phase I/II trials, supported by the early funding from Sila B Health Ventures [F6S]. | The company's explicit roadmap includes primate studies as a next step toward clinical trials, indicating a defined regulatory path [Company site]. |
| Platform Expansion | The validated VLP senolytic platform is applied to other age-related conditions like osteoarthritis, pulmonary fibrosis, or neurodegenerative diseases. | Publication of robust, peer-reviewed data demonstrating selective clearance of senescent cells in the initial atherosclerosis model. | The company's own materials state the platform "could expand to other age-related diseases," framing atherosclerosis as the initial indication [Netcapital]. |
Data Accuracy: YELLOW -- Opportunity framing relies on company-stated plans and preclinical data; market size references are from common industry reports. The platform expansion claim is cited directly from company materials.
Sources
- [Netcapital] Learn about Vertical Longevity Pharma | https://netcapital.com/companies/vertical-longevity
- [Company site] Vertical Longevity Pharma | https://vertical-longevity-pharma.com/
- [The Bioinformatics CRO Podcast] David Scieszka - The Bioinformatics CRO Podcast | https://www.bioinformaticscro.com/podcast/david-scieszka/
- [Kingscrowd, 2025] Vertical Longevity Pharma on NetCapital 2025 | https://kingscrowd.com/vertical-longevity-pharma-on-netcapital-2025/
- [Wixdom] Vertical Longevity Pharma | Wixdom | https://www.wixdom.io/app/offerings/netcapital_vertical_longevity_0
- [F6S] Vertical Longevity Pharmaceuticals | F6S | https://www.f6s.com/company/vertical-longevity-pharmaceuticals
- [American Heart Association] Cardiovascular Disease Cost Burden Report | https://www.heart.org/
- [Longevity.Technology] Longevity Therapeutics Market Analysis | https://www.longevity.technology/
- [Nature Aging] Regulatory Pathways for Aging-Related Therapies | https://www.nature.com/nataging/
- [Crunchbase, 2023] Cleara Biotech Funding | https://www.crunchbase.com/
- [Unity Biotech website] Unity Biotechnology Pipeline | https://www.unitybiotechnology.com/
- [PitchBook, Retrieved 2026] Sila B investment portfolio | PitchBook | https://pitchbook.com/profiles/investor/640045-72
Articles about Vertical Longevity Pharma
- A Senolytic Vaccine Aimed at the Arterial Plaque Itself — Vertical Longevity Pharma, an Irvine preclinical biotech, is engineering virus-like particles to clear the senescent cells driving atherosclerosis.